Subscribe to Ear/Nose/Throat
View Sample

FREE Email Newsletter

New Test to Screen for Glaucoma Damage

June 21, 2011 7:45 am | by Bio-Medicine.Org | News | Comments

PINE BROOK, N.J., June 21, 2011 /- A recent paper published in the Journal of Glaucoma shows a new visual evoked potential (VEP) technique to be a fast, objective method to screen for functional damage in glaucomatous eyes. The technique, called short duration transient VEP (SD-tVEP),...

Maroon 5 Lead Singer Adam Levine Raises Awareness of Attention-Deficit/Hyperactivity Disorder in Young Adults and Adults With "Own It"

June 20, 2011 5:39 am | by Bio-Medicine.Org | News | Comments

PHILADELPHIA, June 20, 2011 /- Adam Levine, lead singer of Maroon 5, is helping to raise awareness among young adults and adults about Attention-Deficit/Hyperactivity Disorder (ADHD) through a new national education campaign called "Own It" that launched today.  The campaign,...

American Medical Systems Announces Large-Scale, Physician-Led Registry of Penile Implants

June 15, 2011 6:33 am | by Bio-Medicine.Org | News | Comments

MINNETONKA, Minn., June 15, 2011 /-   American Medical Systems® (AMS) (NASDAQ: AMMD ), a leading provider of world-class devices and therapies for male and female pelvic health, announced today the commencement of a major global registry of penile prosthetic outcomes.  The...


TomoTherapy Shareholders Approve Accuray Acquisition of TomoTherapy

June 9, 2011 9:36 am | by Bio-Medicine.Org | News | Comments

SUNNYVALE, Calif., June 9, 2011 /- Accuray Incorporated (Nasdaq: ARAY ), a global leader in the field of radiosurgery, announced today that TomoTherapy shareholders have approved the proposed acquisition of TomoTherapy Incorporated (Nasdaq: TOMO ) by Accuray. More than 98 percent of votes...

New Data On Xeomin® (IncobotulinumtoxinA) To Be Presented At The 15th International Congress Of Parkinson's Disease And Movement Disorders (MDS)

June 8, 2011 11:33 am | by Bio-Medicine.Org | News | Comments

FRANKFURT, Germany, June 8, 2011 /- Merz Pharmaceuticals today announced that new data on Xeomin® (incobotulinumtoxinA), a botulinum toxin type A free from accessory (complexing) proteins, will be presented at the Movement Disorder Society's (MDS) 15th International Congress of...

Otonomy Announces Preclinical Results Supporting Intra-operative Use of OTO-201 for Common Childhood Procedure

June 8, 2011 5:34 am | by Bio-Medicine.Org | News | Comments

SAN DIEGO, June 8, 2011 /- Otonomy, Inc., a developer of innovative therapeutics for diseases and disorders of the ear, today announced positive results for OTO-201, a sustained release gel formulation of the antibiotic ciprofloxacin, in multiple preclinical studies evaluating the...

XTRAC Laser Provides New Hope for Children with Psoriasis

June 8, 2011 5:33 am | by Bio-Medicine.Org | News | Comments

MONTGOMERYVILLE, Pa., June 8, 2011 /- About 20,000 children in the United States under the age of 10 are diagnosed with psoriasis every year. For many, the disease goes beyond painful red, dry patches of scaly, thickened skin; the emotional side-effects are equally life...

Edison Pharmaceuticals to Provide Expanded Access to EPI-743 for Mitochondrial Disease

June 7, 2011 11:32 pm | by Bio-Medicine.Org | News | Comments

MOUNTAIN VIEW, Calif., June 8, 2011 /- Edison Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has allowed an Expanded Access program to provide EPI-743 to seriously ill patients diagnosed with inherited respiratory chain diseases of the mitochondria....


The Premier Basketball League Brings on Key Health Industry Sponsorship for 2012

June 6, 2011 2:35 pm | by Bio-Medicine.Org | News | Comments

CHICAGO, June 6, 2011 /- The Premier Basketball League announced today that Scientific Imaginetics® , the global leader in non-invasive pain relief technology, has come on board as a corporate sponsor for the 2012 PBL season. Scientific Imaginetics' TMR® technology is a...

NKTR-102 Demonstrates Sustained Clinical Benefit in 46% of Patients with Metastatic Breast Cancer in Data Presented at 2011 American Society of Clinical Oncology Annual Meetin...

June 4, 2011 11:34 am | by Bio-Medicine.Org | News | Comments

CHICAGO and SAN FRANCISCO, June 4, 2011 /- Nektar Therapeutics (Nasdaq: NKTR ) today announced positive results from a Phase 2 clinical study evaluating single-agent NKTR-102 as a second- and third-line treatment in patients with metastatic breast cancer during the 2011 American Society...

Wake Forest Baptist Medical Center and Cornerstone Pharmaceuticals Present Interim Data From Phase I Trial of CPI-613 in Acute Myeloid Leukemia

June 3, 2011 6:36 am | by Bio-Medicine.Org | News | Comments

CHICAGO, June 3, 2011 /- Cornerstone Pharmaceuticals and Wake Forest Baptist Medical Center today announced key findings from a Phase I clinical trial of Cornerstone's first-in-class cancer metabolism inhibitor drug, CPI-613 in Acute Myeloid Leukemia (AML). Data will be presented at the...

Biocept and Academic Collaborators to Present Poster at ASCO on Circulating Tumor Cells (CTCs)

June 2, 2011 1:33 pm | by Bio-Medicine.Org | News | Comments

SAN DIEGO, June 2, 2011 /- Biocept, Inc. today reported that its scientists and academic collaborators will present a poster at the 2011 Annual Meeting of the American Society of Clinical Oncology (ASCO) taking place in Chicago, Illinois June 3-7. The poster presentation is based on...

At SIIM 2011 Siemens Showcases Imaging IT Solutions for Driving Greater Value in Radiology and Other Specialties

June 2, 2011 6:34 am | by Bio-Medicine.Org | News | Comments

WASHINGTON, June 2, 2011 /- Siemens Healthcare (NYSE: SI) will showcase its portfolio of imaging information technology (IT) and workflow management solutions at the Society for Imaging Informatics in Medicine (SIIM) 2011 Annual Meeting from June 2-5, 2011, (booth 825) in the Gaylord...


CSL Behring Receives EU Orphan Drug Designations for rVIIa-FP for Hemophilia A and B Treatment

May 31, 2011 6:33 am | by Bio-Medicine.Org | News | Comments

KING OF PRUSSIA, Pa., May 31, 2011 /- CSL Behring announced today that it has been granted Orphan Drug Designations (ODD) by the European Commission for the development of its recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP), a novel therapy to treat...

Brin Wojcicki Foundation Announces $50-Million Challenge Grant to Michael J. Fox Foundation to Spur Progress Toward Parkinson's Cure

May 31, 2011 6:32 am | by Bio-Medicine.Org | News | Comments

NEW YORK, May 31, 2011 /PRNewswire-USNewswire/ --Sergey Brin and Anne Wojcicki announced a $50-million challenge spurring existing and new donors at every level to give, or increase giving, to The Michael J. Fox Foundation for Parkinson's Research (MJFF). The Challenge is now in effect...

Bayer's Discrimination Lawsuit Now Requires Extra-Strength Cure

May 25, 2011 11:33 am | by Bio-Medicine.Org | News | Comments

NEWARK, N.J., May 25, 2011 /- Just days after the one year anniversary of winning a $250 million verdict for female sales representatives at Novartis Pharmaceuticals Corporation, the law firm of Sanford Wittels & Heisler LLP filed a nearly identical class action on behalf of female...

XDATA Retains Adapt IP Ventures to Market Patents and Technology for Automated 3D Ultrasound Imaging System

May 25, 2011 4:33 am | by Bio-Medicine.Org | News | Comments

ATLANTA, May 25, 2011 /- XDATA retains Adapt IP Ventures to market XDATA's intellectual property including patents and fully-functioning prototype focused on breast cancer detection. Over many decades, XDATA has developed, patented and tested methods and devices for automatically...

An X Prize for Mobile Diagnostics

May 22, 2011 8:35 pm | by Massachusetts Institute of Technology | News | Comments

A $10 million prize would go to the first device that can diagnose a range of diseases with the same accuracy as a team of doctors.

Red Hill Studios/UCSF Partnership to Showcase 'Gaming Therapy' for People With Parkinson's Disease at Games for Health Conference

May 16, 2011 12:34 pm | by Bio-Medicine.Org | News | Comments

BOSTON, May 16, 2011 /- Red Hill Studios, in partnership with the UCSF School of Nursing, will showcase a custom suite of Kinect™-based physical therapy games that have been specifically designed to help people with Parkinson's slow the progression of this neurodegenerative disease....

AlphaDetail AlphaPulseâ„¢: Anticipated Impact of CATT Trial in Wet AMD Treatment

May 16, 2011 5:35 am | by Bio-Medicine.Org | News | Comments

SAN MATEO, Calif., May 16, 2011 /- On April 28, 2011 the New England Journal of Medicine released highly anticipated one-year results of the ongoing "Comparisons of Age-Related Macular Degeneration Treatments Trials" (CATT). AlphaDetail, Inc., a leader in global ophthalmology primary...

Simpler Genome Sequencing

May 13, 2011 2:35 pm | by Massachusetts Institute of Technology | News | Comments

A startup hopes to make the technology cheap enough that it's feasible for a typical hospital lab.

FDA Approves Novartis Drug Afinitor to Treat Pancreatic Neuroendocrine Tumors

May 6, 2011 6:42 am | by Bio-Medicine.Org | News | Comments

MANHATTAN BEACH, Calif., May 6, 2011 /- Yesterday, the U.S. Food and Drug Administration (FDA) approved the Novartis drug Afinitor® (everolimus) for the treatment of advanced pancreatic neuroendocrine tumors.  Neuroendocrine tumors make up less than five percent of all...

Novartis Gains FDA Approval for Afinitor® as First New Treatment in Nearly Three Decades for Patients with Advanced Pancreatic NET

May 5, 2011 5:35 pm | by Bio-Medicine.Org | News | Comments

EAST HANOVER, N.J., May 5, 2011 /- Novartis Pharmaceuticals Corporation ("Novartis") announced today that the US Food and Drug Administration (FDA) approved Afinitor® (everolimus) tablets for the treatment of progressive neuroendocrine tumors of pancreatic origin (PNET) in patients...

New CE Marked Test Simultaneously Detects Up To 95% of Gastrointestinal Infections in Under Five Hours

May 4, 2011 10:40 pm | by Bio-Medicine.Org | News | Comments

AUSTIN, Texas and MILAN, May 5, 2011 /- Luminex Corporation (NASDAQ: LMNX ) announced today that it has received CE marking for its new xTAG Gastrointestinal Pathogen Panel (GPP).This innovative assay is the first test of its kind to help identify up to 95 percent of the disease causing...

Immunetics lands $2.4M NIH grant for parasite detection

May 3, 2011 7:34 am | by Mass High Tech: The Journal of New England Technology | News | Comments

Infectious disease testing company Immunetics Inc. has won a three-year, $2.4 million Phase 2 SBIR grant from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.